Aehr has been a wild ride since it’s last earnings report. The orders that came in were substantial, including a $25 million order from ON Semi. This order alone is 50% of last year’s $50M in revenue. The company was in the crosshairs of Tesla’s comments about a reduction in silicon carbide in their lower-tier models, and was also in the crosshairs of the failure of Silicon Valley Bank. When it seemed the stock simply couldn’t go any higher, it defied the odds, and marched higher.
Now, the market is shaking the stock loose on an excellent earnings report. Welcome to the world of small caps. The headlines are pointing toward the CFO leaving, but it’s not a real concern as he’s retiring and not moving onto a new company.
In a nutshell, the company beat on the top line and the bottom line plus reported strong margin expansion year-over-year. Compared to fiscal Q2, the margins were softer by 220 bps on gross margin, 150 bps on operating margin and 150 bps on net margin. This would be nitpicking the report, because on a YoY basis, the margins have expanded nicely (more below).
AEHR is not raising full year guidance despite beating on the top line. This implies $17.3 million to $27.3 million in revenue for next quarter. This compares to $17.2 million this quarter and $20.2 million in the year ago quarter. The high end of this guidance is not a problem given it would represent YoY and QoQ growth. However, given Aehr’s valuation, next year’s fiscal guide from management is where the market may be a touch nervous.
Bookings and backlog were very healthy this quarter (best in company history), which helps in the absence of management pulling forward the current quarter’s revenue beat. One thing to watch is that customer deposits were down, I quote the CEO on this below.
I do think it’s “all eyes” on the next fiscal year guide in July for a few reasons.
- There are only two analysts covering the stock. Management’s input on what to expect is outsized, in this case. The fiscal year consensus for the 2 analysts is $102.3 million, for growth of 56.8%. This is a sizable hurdle to clear (will be up from roughly 29% growth this year), and with 1 quarter to go before management gives it’s guide, the market likely wants confirmation they can clear this expectation.
- Management has referenced a strong H2 2023/2024 and this will help quantify those comments.
- The valuation is quite high, and to support this, a fiscal year guide from management is very much needed come July.
Financials:
Aehr reported revenue of $17.2 million, for growth of 13% year-over-year and sequential growth of 16%. As stated above, the company did not raise full year guidance, rather reiterated “total revenue of at least $60 to $70 million, representing growth of 18% to 38% YoY, with strong profit margins similar to last year.”
EPS of $0.16 came in slightly higher than expected. This is up from $0.14 EPS from a year ago. The margins saw a turnaround in CY2021 (post-Covid) when margins were negative. This quarter was aligned with the new trend toward margin expansion for the company.
Margins:
- Gross margin of 51.6% up from 48.6% in the year ago quarter. Last quarter, the GM was 53.40% softer by 180 bps
- Operating margin of 22% up from 14.8% in the year ago quarter. Last quarter, the OPM was 23.50% softer by 150 bps
- Net income margin of 23.8% is up from 14.7% in the year ago quarter. Last quarter, net profit margin was 25.30%.
On the margins, management pointed toward a slight increase in SG&A and R&D for the QoQ change. On net income, the GAAP includes a $1M adjustment for excess and obsolete inventory.
Cash:
Free cash flow will be available in the 10-Q that is filed over the next two weeks.
The August quarter reported cash flow margins of 50% which offset the other quarters:
- In the year ago quarter ending in February, the company reported operating cash flow of (19.2%) and FCF margin of (19.7%). This was roughly ($3M)
- Last quarter, the company reported operating cash flow of (1.3%) and free cash flow of (1.4%). This was roughly ($200K).
The cash has increased to $42.8 million, up from $36.6 million last quarter. This is due to the agreement for a $25 million at-the-market offering, of which $7.3 million was sold last month at a share price of $34.78. This leaves $17.7M remaining. There is dilution of 2.4%.
Key Metrics:
This earnings report stood out in terms of key metrics. Bookings were the highest in company history at $33 million, up from $10.8 million last quarter. This puts the three quarters of fiscal year to-date at $72 million, compared to $62.2 million for the entire fiscal year last year.
The backlog is at $31.6 million with an effective backlog of $41 million. The backlog in the year ago quarter was $26.9 million, and the effective backlog was “over $30 million.”
Inventories are ticking up, which can often be seen as a negative (company like Micron participating in a cyclical slowdown). For Aehr, it’s good to have inventory on-hand for any spikes in demand. Inventories were at $21.6 million, up from $3.6 million last quarter and up $6.5 million in the year ago quarter. This is only 1/5th of next year’s fiscal consensus estimate of $102 million.
In the last earnings call, the following was stated:
“This quarter, AEHR discussed ramping inventory by an additional $5 million (so far) year-over-year in Q2: “We are increasing inventory to support our expected growth in the second half of fiscal 2023, and we continue to purchase inventory to ensure adequate supply to meet current customer and future customer market demand.”
Aehr’s management is optimistic for H2, which we reported on in the last earnings write-up.
“The company mentioned “momentum into 2024” in this call: “And as we had — if you look at the amount of capacity that everybody’s talking about to hit in 2025 calendar-wise, most people are just really focused on second half 2023 and into 2024 is where just a lot of capacity is coming online and so it may be less to do with the timing of us as the timing of that silicon carbide ramp. And our goal is to get qualified before that ramp happens and have a ton of capacity and material on hand to be able to address it.”
This quarter, Aehr discussed ramping inventory by an additional $5 million (so far) year-over-year in Q2: “We are increasing inventory to support our expected growth in the second half of fiscal 2023, and we continue to purchase inventory to ensure adequate supply to meet current customer and future customer market demand.”
Earnings Call:
Current Fiscal Year Guide:
Here’s a question from one of the analysts that cover the stock on the current fiscal year guide still looking conservative and he also notes the wide range:
“Jed Dorsheimer
So I guess first question, Gayn or maybe Ken, maybe you want to take either one. But the guide and kind of reiterating the numbers suggest a pretty wide variance at this stage in the game, $17 million to $27 million […] And I know that there were two tools with the — that we weren’t — that you weren’t sure were not you get the rev rec to fall into the quarter. But I am wondering, is that the only thing that sort of kind of the difference of that $10 million or is there something else that you can probably provide a bit more color on?”
Gayn Erickson
“Aehr Test along with most, I think, all capital equipment companies have revenue recognition policies related to when you can score revenue and that is different than when you get paid by the way. Our policy, I think, is very conservative. If we have a new product, particularly to a new customer, but if we have a brand new product that has never been proven or installed and accepted by the customer, we simply don’t take revenue for it until that milestone, even though we know it’s working here, it’s been completely proven out, et cetera, but until the customer actually signs off on it, we won’t score revenue recognition. And we gave that as a pretty big heads-up going in. That’s why a lot more detail than normal, and candidly, we will probably be pulling back on detail related to things. It’s just to make sure that our shareholders understand that we have got some pretty large revenue number of things that are shipping during the quarter, but may or may not score revenue.
And you have several multimillion-dollar tool that misses by a few days and it’s pretty easy. What I want to make sure that and I will be explicit even though it’s just been implied, we are just talking about whether it comes in, in Q4 or Q1. So that’s the bulk of it.”
Jed Dorsheimer
No. The color is helpful. So thank you. I guess if you could just help me reconcile just two moving parts. Inventory, not surprisingly picked up as you talked about in terms of ramping some of these products, but customer deposits dropped off on the balance sheet. I was wondering if you could just provide a bit more color there. Is that a timing issue or how should we read those two vectors, if you will?
Gayn Erickson
Yeah. That’s a good observation and good to move in [ph]. So we actually have taken with some specific terms and conditions with customers. There are circumstances where we do not take down payments. It’s a pretty good threshold contractually for them to actually do that.
I have also at times on a brand-new product with a new customer, waived the down payment to begin with, because it’s a little odd to tell them we guarantee it’s going to work and then at the same time, we holding their money.
And candidly, people are pushing back harder and harder on some of those deposits. Ken, I think, a lot of it is that they can earn a lot more money on that too. But there’s a little bit of examples where some of the backlog is not all out of deposit and that’s what you are seeing.
New Customers, New Products and New Markets:
Aehr has four committed customers for silicon carbide. Per the CEO: “We have actually announced a total of four customers in silicon carbide so far. We expect production orders from all of them during the next fiscal year.” One of these customers has not announced it’s in the silicon carbide market yet.
Gallium Nitride is getting more air time on the earnings call. From the sound of it, this will be the next market Aehr participates in a meaningful way.
“In addition to our momentum in silicon carbide, we are now engaged with several gallium nitride semiconductor suppliers ranging from radio frequency or RF devices to power devices. Since our last call, we also received a firm commitment from a very large multinational semiconductor supplier to move forward with a full wafer level evaluation of gallium nitride devices. This evaluation includes our new high voltage option for doing the critical HTRB stress needed for gallium nitride MOSFETs and amplifiers.
We believe gallium nitride will be a significant market, driven by some of the very — some very high volume applications such as RF amplifiers, consumer, electronic power converters and chargers, solar power inverters and charger and converter applications in both standard and electric vehicles. Feedback from companies has been that several of these applications will require production burn-in to meet the application’s critical quality and reliability needs.”
On the topic of silicon photonics … the CEO said “while we believe this transition is still several years out”, yet did state they have 6 potential customers: “Aehr currently has systems installed at over half a dozen customers for 100% test and burn-in of silicon photonics devices used in 5G infrastructure, data and telecommunication transceivers and a few additional applications yet to be introduced.” They also specifically name dropped Intel, Nvidia and AMD for plans to “integrate silicon photonics transceivers into their microprocessors, graphics processors and chipsets.”
China was talked about quite a bit.
The far majority of Aehr’s business comes from outside of China, but Aehr believes over time, the company will serve this market for silicon carbide.
“We are also talking to suppliers in China, as well as OEMs in China. So we are kind of making our way up the food chain, if you will, with several conversations with Tier 1s and OEMs, which as people that are close to this realize that is a completely new thing.
Prior to COVID, none of the automotive guys talk to the semiconductor guys, right? They all worked with Tier 1s and then the Tier 1s bought from the semiconductor guys. But with all the craziness that went on supply chain, automotive guys who realize they need to go directly to and talk to the semiconductor guys. Well, we are taking a step further, they are talking to us […] Having said that, we are very confident in next year and how things are going and candidly, without trying to be in a significant portion of it, I would say that would be upside to our plans.”
Please note:
These new markets, new products and new customers are exciting, yet we have emphasized many times that the majority of Aehr’s revenue comes from one customer today — On Semi. There is customer concentration risk. We want to weigh what drives revenue at the company today alongside what can move the needle over the next year. We are comfortable with this risk, each I/O Fund Member will need to decide for themselves what their risk tolerance is around high customer concentration.
Conclusion:
Aehr is a company where technicals are going to be of utmost importance as we surf the silicon carbide wave. Per our last earnings report write-up: “We took gains in AEHR recently because we felt it was the responsible thing to do. The small cap had grown to be the top leading position in our portfolio. However, we’d like to build back at key times as the company is doing all the right things.”
Some rough numbers: The stock is up 68% since the last earnings report when I stated we took gains – that 68% includes today’s (15% pullback). We have been reducing our position since late November, not out of lack of conviction, but because we feel it’s the responsible thing to do. We then attempted a 1% breakout.
My point is that small caps are one where investors should determine how they want to play this. Going long and strong with a company that has this kind of TAM is understandable. SiC wafer market is expected to grow 35X by 2030 – that’s not a typo. “Forecast from William Blair estimate that the silicon carbide market for devices in electric vehicles alone, such as traction inverters and onboard chargers is expected to grow from 119,000 6-inch equivalent silicon carbide wafers for EVs in 2021 to more than 4.1 million 6-inch equivalent wafers in 2030, representing a compound annual growth rate of 48.4%. This equates to almost 35 times larger in 2030 than in 2021.”
Notably, Aehr’s wheels fell off last year and it dropped (70%) with no real notable change in the story. Many investors will look for a “why” but it’s the nature of small caps facing macro headwinds, which results in a risk-off appetite. Even if an investor thinks they are mentally prepared for this, it’s extremely uncomfortable when a selloff in small caps (and other larger tech stocks) actually happens.
We prefer to be in the middle with this stock – we are going to participate heavily at times (it grew to be our number one position) but also try to take gains when we can. The company is trading at a forward P/S of 13. The stock is much safer under a 10 forward P/S and safer yet under a 6 forward P/S. If we get into this range, you’ll probably see quite a few buy alerts.

The Forward PE Ratio is similar – not much history holding at this level.

The fiscal year guide is very important because it will lay the foundation for the stock’s valuation. If the guide is higher than analysts are forecasting, then these valuations get cheaper overnight. The orders that are announced throughout the quarter help, in this regard. The risk would be a lower FY2024 guide (given only two analysts cover the stock) and valuations will be forced to get cheaper. Hence, there is some buildup going into the July call.
Additional Information on Orders and Recent Headlines:
Note: we’ve spoken about this throughout the quarter, listed here for reference purposes.
For a small cap, Aehr has had to weather quite a few headlines this past quarter.
Aehr holds a credit line and checking account at Silicon Valley Bank. The official statement from the company is the following:
- “Aehr Test does have a checking account at SVB with a current balance of under $2.5 million, which is less than 6% of our total of $41.8M in cash and short-term liquid assets”
- “Aehr has over $39.3 million in another financial institution which includes over $9.7 million in cash and $29.6 million in short term US Government backed Treasury Bonds.”
- “Aehr has no outstanding balance on its line of credit with Silicon Valley Bank and foresees no need to draw on the line in the near future. Aehr believes that there is no impact to our operations, customers, vendors, or employees. We are taking all appropriate steps to prevent any impact on our operations.”
The second headline, which had a larger impact on daily price movement, was Elon Musk’s comments about reducing the need for silicon carbide. Management was quick to respond with the following:
- “Tesla clarified that this will not impact the current high-performance model platforms including the Model S/X and Model 3/Y vehicles. Also, we believe that the new chips in the lower cost models will be 100 Amps per device versus 50 Amps per device today and likely 50% or more larger in surface area; therefore, the number of wafers required will be less impacted”
- “This is important as Aehr’s total available market is primarily driven by the number of wafers required, not the number of devices”
- “It is also important to understand that a 100A device using today’s generation of silicon carbide devices is approximately 50% larger than the devices used in the current Telsa inverters. So, while this new lower performance 800 kVa inverter only uses 12 die or 75% less than the current 48 die design, the die themselves are estimated to be about 50% larger, or require 50% more wafers for the same number of die.”
- “In addition, during the Q&A session, Tesla further clarified that the new inverters would be made from a new Tesla-proprietary custom module package, and that Tesla would purchase the die from multiple manufacturers and package them in this Tesla-proprietary custom module. Again, Aehr sees this as a natural roadmap and consistent with the roadmaps stated by major manufacturers of silicon carbide where the electric vehicle inverters will migrate multi-chip modules to reduce power conversion losses, improve thermal performance, simplify design, and lower overall cost of the inverter system. As companies migrate to silicon carbide modules with multiple die in a single module package, the need for wafer level test and burn-in become critical to ensuring automotive quality and reliability as well as cost as the yield loss as a result of the stress test induced failures during burn-in become extremely expensive as a single die failure in a module results in throwing away the entire module including the other die in the module. Therefore, we believe the business use case for our solution actually increases. Wafer level test and burn in of 100% of die and extended burn in times will be required to earn Tesla’s business.
Orders Since the Last Earnings Report
- In January, AEHR received a $25.1 million order for FOX-XP Test and Burn-in Systems. This will include a later order of the WaferPaks (the razor-razor blade model). The customer was ON Semi, per the CEO stating it came from their “lead silicon carbide customer”
- A little more than a week ago, AEHR received a Volume Production Order from a “Major Silicon Carbide Customer” – this was not ON Semi as it was stated it came from Aehr’s “second major silicon carbide semiconductor customer.” The shipments are expected to begin March 1st.
- In March, Aehr also received an additional $6.7 million order from ON Semi.
- In January, Aehr announced a new customer that supplies both silicon carbide and gallium nitride semiconductors.





























































